Navigation Links
3SBio Inc. Files for SFDA Approval of NuLeusin
Date:11/10/2008

SHENYANG, China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA) for approval of NuLeusin for the treatment of late stage metastatic renal cell carcinoma. If approved, NuLeusin is expected to be the only treatment of this kind available in China.

NuLeusin, 3SBio's second-generation IL-2, is a genetically modified form of IL-2 possessing improved biochemical properties over naturally occurring IL-2. Clinical trials examined the safety and efficacy of two treatment cycles of subcutaneous injections of NuLeusin. During each six-week treatment cycle, patients were given daily doses of 7MIU/square meter in the induction phase and daily doses of 3.5MIU/square meter in the maintenance phase. The results showed an overall efficacy (Complete Response +Partial Response) of 12.73% and a disease control rate (Complete Response+ Partial Response+ Stable Disease) of 60%. Compared to Chiron's Proleukin, a treatment available in the United States, which is believed to be the only similar product on the market today, Nuleusin demonstrated similar levels of efficacy with a much lower dosage. More importantly, NuLeusin showed an improved safety and tolerability profile in patients who participated in the Phase III study.

"Today's submission comes only a little over one month following our submission for high dosage EPIAO and once again demonstrates our outstanding research and development capabilities and our strong ability to execute on our business plan," stated Dr. Jing Lou, Chief Executive Officer of 3SBio. "NuLeusin was developed to provide a new immunotherapy regimen for oncologists to treat patients with late stage metastatic renal cell carcinoma. Upon approval, we believe many patients who have exhausted their trea
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
2. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
3. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
4. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
5. 3SBio Inc. Announces Results of Annual General Meeting
6. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. Announces Second Quarter 2008 Results
9. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
10. 3SBio Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
11. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... Z Trim Holdings, Inc. (OTC Markets: ZTHO), ... of industries, announced that Chef Erin Ryan ... year,s National Restaurant Association ("NRA") NRA Show, which was ... Research Chefs Association.  Chef Ryan spoke on the subject ... and the Ugly," joining four other prestigious panelists including: ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... Fla., July 2 Bioheart, Inc. (Nasdaq:,BHRT) a ... of,autologous (patient-derived) cell therapies and devices for the ... it has been added to the,Russell Microcap Index ... of U.S. and global equity indexes on June ...
... Pharma, a leading provider of,knowledge management solutions to ... that the Aureus Pharma 2008 User Symposium will,be ... This symposium follows last year,s highly successful ... pharmaceutical and biotech customers,from both Europe and North ...
... 2 Research conducted at The,Walter and ... to a,major licensing agreement signed between Australian ... Merck,Serono., Under the Development and Licensing ... treatments for multiple sclerosis (MS) and other ...
Cached Biology Technology:Bioheart, Inc., Added to Russell Microcap Index 2Aureus Pharma Announces Date of 2008 Annual User Symposium 2MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2
(Date:5/23/2013)... fastest growing open-access publishers, announces the launch of ... Biotechnology . , A broad scope journal ... Biotechnology will provide a single open-access platform ... to be disseminated and discussed. , ... an open-science and interactive web platform for the ...
(Date:5/23/2013)... an age when microbial pathogens are growing increasingly resistant ... a team of Wisconsin scientists has synthesized a potent ... that cause staph infections. , Writing online in the ... group led by University of Wisconsin-Madison chemistry Professor Helen ... sensing" behavior of Staphylococcus aureus , a bacterium ...
(Date:5/22/2013)... Lung Screening Trial (NLST) investigators also conclude that ... with low-dose computed tomography (LDCT) versus chest X-ray ... paper is achievable at experienced screening centers in ... information to share with their patients about the ... following today,s publication in the New England ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... DC Could some women who naturally produce excess ... developing breast cancer? Results of a new animal study ... Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown ... August 15 Cancer Research, the investigators say ...
... North American Societies provides a comprehensive and in-depth documentation ... adapting to the varied ecosystems of North America during ... of recurrent themes and questions that have shaped debates ... impact on their local environments throughout the Holocene. ...
... (Vancouver August 11, 2011) Pregnant women taking prenatal ... new Vancouver-based study led by the Child & Family Research ... Canadian Journal of Public Health . The study ... reported taking supplements containing vitamin D, many were vitamin D ...
Cached Biology News:Higher estrogen production in the breast could confer greater cancer risk than thought 2Higher estrogen production in the breast could confer greater cancer risk than thought 3Pregnant women in Vancouver may not be getting enough vitamin D 2
... Blocker Arrays can be used to ... various proteins and sera that are commonly ... The array contains spots for 21 different ... Determination of antibody crossreactivity and species specificity, ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
... offers a full length insert sequencing service ... cosmids and fosmids. Agencourt utilizes unique ... libraries. There are several features that ... data with rapid turnaround including our patented ...
... maintenance, calibration, and validation (MCV) ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...
Biology Products: